코로나바이러스감염증-19(SARS-CoV-2 감염증)의 임상 양상과 치료

키워드

참고문헌 (64)

1. Lu H, "Outbreak of pneumonia of unknown etiology in Wuhan, China : the mystery and the miracle", J Med Virol, 92(4), pp.401~402 (2020)
2. "Timeline: WHO’s COVID-19response" (2020)[URL]
3. "WHO Coronavirus Disease (COVID-19) Dashboard" (2020)[URL]
4. "코로나바이러스감염증-19 (COVID-19)" (2020)[URL]
5. Chan JF, "A familial cluster of pneumonia associated with the 2019novel coronavirus indicating person-to-person transmission:a study of a family cluster", Lancet (London, England), 395(10223), pp.514~523 (2020)
6. Ren LL, "Identification of a novel coronavirus causing severe pneumonia in human : a descriptive study", Chin Med J, 133(9), pp.1015~1024 (2020)
7. Gorbalenya AE, "The species severe acute respiratory syndrome-related coronavirus : classifying 2019-nCoV and naming it SARS-CoV-2", Nat Microbiol, 5(4), pp.536~544 (2020)
8. Chu DK, "Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis", Lancet (London, England), 395(10242), pp.1973~1987 (2020)
9. He X, "Temporal dynamics in viral shedding and transmissibility of COVID-19", Nat Med, 26(5), pp.672~675 (2020)
10. Wölfel R, "Virological assessment of hospitalized patients with COVID-2019", Nature, 581(7809), pp.465~469 (2020)
11. Ganyani T, "Estimating the generation interval for coronavirus disease (COVID-19) based on symptom onset data, March 2020", Euro surveillance: bulletin Europeen sur les maladies transmissibles = European Communicable Disease Bulletin, 25(17) (2020)
12. Sun J, "Prolonged persistence of SARS-CoV-2 RNA in body fluids", Emerg Infect Dis, 26(8), pp.1834~1838 (2020)
13. Cheng HY, "Contact tracing assessment of COVID-19 transmission dynamics in Taiwan and risk at different exposure periods before and after symptom onset", J JAMA Intern Med, 180(9), pp.1156~1163 (2020)
15. van der Vries E, "Prolonged influenza virus shedding and emergence of antiviral resistance in immunocompromised patients and ferrets", PLoS Pathog, 9(5), pp.e1003343~ (2013)
16. Bansal A, "Coronavirus disease 2019 Pneumonia in immunosuppressed renal transplant recipients : a summary of 10confirmed cases in Wuhan, China", Eur Urol, 77, pp.748~754 (2020)
17. Lee YL, "Dynamics of anti-SARS-Cov-2 IgM and IgG antibodies among COVID-19 patients", J Infect, 81(2), pp.e55~8 (2020)
18. van Kampen JJA, "Shedding of infectious virus in hospitalized patients with coronavirus disease-2019(COVID-19): duration and key determinants", medRxiv, ~ (2020)
20. Guo ZD, "Aerosol and surface distribution of severe acute respiratory syndrome coronavirus 2 in hospital wards, Wuhan, China, 2020", Emerg Infect Dis, 26(7), pp.1583~1591 (2020)
21. Lednicky JA, "Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients", Int J Infect Dis, 100, pp.476~482 (2020)
22. Chou R, "Masks for prevention of respiratory virus infections, Including SARS-CoV-2, in health care and community settings : a living rapid review", Ann Intern Med, 173(7), pp.542~555 (2020)
23. Lee JK, "Wearing face masks regardless of symptoms is crucial for preventing the spread of COVID-19 in hospitals", Infect Control Hosp Epidemiol, pp.1~2 (2020)
24. Lyu W, "Community use of face masks and COVID-19: evidence from a natural experiment of state mandates In the US", Health Aff (Millwood), 39(8), pp.1419~1425 (2020)
25. Wang Y, "Reduction of secondary transmission of SARS-CoV-2 in households by face mask use, disinfection and social distancing : a cohort study in Beijing, China", BMJ Glob Health, 5(5), pp.e002794~ (2020)
26. van Doremalen N, "Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1", N Engl J Med, 382(16), pp.1564~1567 (2020)
27. Cai J, "Indirect virus transmission in cluster of COVID-19 cases, Wenzhou, China, 2020", Emerg Infect Dis, 26(6), pp.1343~1345 (2020)
28. Chen H, "Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women : a retrospective review of medical records", Lancet, 395(10226), pp.809~815 (2020)
29. Dashraath P, "Coronavirus disease 2019(COVID-19)pandemic and pregnancy", Am J Obstet Gynecol, 222(6), pp.521~531 (2020)
30. Zeng L, "Neonatal early-onset infection with SARS-CoV-2 in 33 neonates born to mothers with COVID-19 in Wuhan, China", JAMA Pediatr, 174(7), pp.722~725 (2020)
31. Sung Ho Kyung, "Clinical Course and Outcomes of 3,060 Patients with Coronavirus Disease 2019 in Korea, January–May 2020", Journal of Korean Medical Science, 35(30), pp.1~11 (2020), 대한의학회[DOI]
32. The novel coronavirus pneumonia emergency response epidemiology team, "The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020", China CDC Weekly, 2, pp.1~10 (2020)
33. Guan WJ, "Clinical characteristics of coronavirus disease 2019 in China", N Engl J Med, 382(18), pp.1708~1720 (2020)
34. Lauer SA, "The incubation period of coronavirus disease 2019(COVID-19)from publicly reported confirmed cases : estimation and application", Ann Intern Med, 172(9), pp.577~582 (2020)
35. Docherty AB, "Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol : prospective observational cohort study", BMJ, 369, pp.m1985~ (2020)
36. Garg S, "Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019-COVID-NET, 14 States, march 1-30, 2020", MMWR Morb Mortal Wkly Rep, 69(15), pp.458~464 (2020)
37. Richardson S, "Presenting characteristics, comorbidities, and outcomes among 5, 700 patients hospitalized with COVID-19 in the New York city area", JAMA, 323(20), pp.2052~2059 (2020)
38. Grasselli G, "Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy", JAMA, 323(16), pp.1574~1581 (2020)
39. Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", Lancet, 395(10223), pp.497~506 (2020)
40. Giacomelli A, "Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection : a cross-sectional study", Clin Infect Dis, 71(15), pp.889~890 (2020)
41. Helms J, "Neurologic features in severe SARSCoV-2 infection", N Engl J Med, 382(23), pp.2268~2270 (2020)
42. Lechien JR, "Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease(COVID-19) : a multicenter European study", E Eur Arch Otorhinolaryngol, 277(8), pp.2251~2261 (2020)
43. Spinato G, "Alterations in smell or taste in mildly symptomatic outpatients with SARS-CoV-2 infection", JAMA, 323(20), pp.2089~2090 (2020)
44. Butt N, "Cardiovascular complications in COVID-19", Am J Emerg Med (2020)
45. Hendren NS, "Description and proposed management of the acute COVID-19 cardiovascular syndrome", Circulation, 141(23), pp.1903~1914 (2020)
46. Mao L, "Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China", JAMA Neurol, 77(6), pp.683~690 (2020)
47. Ackermann M, "Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19", N Engl J Med, 383(2), pp.120~128 (2020)
48. Tang N, "Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia", J Thromb Haemost, 18(4), pp.844~847 (2020)
49. Middeldorp S, "Incidence of venous thromboembolism in hospitalized patients with COVID-19", J Thromb Haemost, 18(8), pp.1995~2002 (2020)
50. Rodriguez-Morales AJ, "Clinical, laboratory and imaging features of COVID-19 : a systematic review and meta-analysis", Travel Med Infect Dis, 34, pp.101623~ (2020)
51. Shi H, "Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China : a descriptive study", The Lancet Infectious diseases, 20(4), pp.425~434 (2020)
52. Alhazzani W, "Surviving sepsis campaign : guidelines on the management of critically ill adults with coronavirus disease 2019(COVID-19)", Intensive Care Med, 46(5), pp.854~887 (2020)
53. "oronavirus Drug and Treatment Tracker" (2020)[URL]
54. Geleris J, "Observational study of hydroxychloroquine in hospitalized patients with Covid-19", N Engl J Med, 382(25), pp.2411~2418 (2020)
55. Rosenberg ES, "Association of treatment With hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State", JAMA, 323(24), pp.2493~2502 (2020)
56. Tang W, "Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019 : open label, randomised controlled trial", BMJ, 369, pp.m1849~ (2020)
57. Cao B, "A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19", N Engl J Med, 382(19), pp.1787~1799 (2020)
58. RECOVERY Collaborative Group, "Lopinavir-ritonavir in patients admitted to hospital with COVID-19(RECOVERY) : a randomised, controlled, open-label, platform trial", Lancet, 396(10259), pp.1345~1352 (2020)
59. Mulangu S, "A randomized, controlled trial of ebola virus disease therapeutics", N Engl J Med, 381(24), pp.2293~2303 (2019)
60. Wang M, "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus(2019-nCoV)in vitro", Cell Res, 30(3), pp.269~271 (2020)
61. Beigel JH, "Remdesivir for the Treatment of Covid-19-Final Report", N Engl J Med, 383(19), pp.1813~1826 (2020)
62. Spinner CD, "Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19 : a randomized clinical trial", JAMA, 324(11), pp.1048~1057 (2020)
63. Xu Z, "Pathological findings of COVID-19 associated with acute respiratory distress syndrome", Lancet Respir Med, 8(4), pp.420~422 (2020)
64. Horby P, "Dexamethasone in hospitalized patients with Covid-19-preliminary eport", N Engl J Med, pp.2021436~ (2020)

관련 논문AI추천